Search

Your search keyword '"Rodrigues, Filipe"' showing total 39 results
Start Over Author "Rodrigues, Filipe" Publisher wiley
39 results on '"Rodrigues, Filipe"'

9. An MDS Evidence‐Based Review on Treatments for Huntington's Disease

Author

Ferreira, Joaquim J., primary, Rodrigues, Filipe B., additional, Duarte, Gonçalo S., additional, Mestre, Tiago A., additional, Bachoud‐Levi, Anne‐Catherine, additional, Bentivoglio, Anna Rita, additional, Burgunder, Jean‐Marc, additional, Cardoso, Francisco, additional, Claassen, Daniel O., additional, Landwehrmeyer, G. Bernard, additional, Kulisevsky, Jaime, additional, Nirenberg, Melissa J., additional, Rosser, Anne, additional, Roth, Jan, additional, Seppi, Klaus, additional, Slawek, Jaroslaw, additional, Furr‐Stimming, Erin, additional, Tabrizi, Sarah J., additional, Walker, Francis O., additional, Vandenberghe, Wim, additional, Costa, João, additional, and Sampaio, Cristina, additional

Published
2021
Full Text
View/download PDF

11. Growth and renal function dynamics of renal oncocytomas in patients on active surveillance

Author

Neves, Joana B., primary, Varley, Rebecca, additional, Agnesi, Stefano, additional, Withington, John, additional, Rodrigues, Filipe B., additional, Warren, Hannah, additional, Yuminaga, Yuigi, additional, Capitanio, Umberto, additional, Rode, Nicola, additional, Grant, Lee, additional, Tran‐Dang, My‐Anh, additional, El‐Sheikh, Soha, additional, Walkden, Miles, additional, Cullen, David, additional, Aitchison, Michael, additional, Patki, Prasad, additional, Mumtaz, Faiz, additional, Barod, Ravi, additional, Bex, Axel, additional, and Tran, Maxine G. B., additional

Published
2021
Full Text
View/download PDF

12. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease

Author

Rodrigues, Filipe B., primary, Byrne, Lauren M., additional, Lowe, Alexander J., additional, Tortelli, Rosanna, additional, Heins, Mariette, additional, Flik, Gunnar, additional, Johnson, Eileanoir B., additional, De Vita, Enrico, additional, Scahill, Rachael I., additional, Giorgini, Flaviano, additional, and Wild, Edward J., additional

Published
2021
Full Text
View/download PDF

14. Botulinum toxin type A therapy for blepharospasm

Author

Duarte, Gonçalo S, additional, Rodrigues, Filipe B, additional, Marques, Raquel E, additional, Castelão, Mafalda, additional, Ferreira, Joaquim, additional, Sampaio, Cristina, additional, Moore, Austen P, additional, and Costa, João, additional

Published
2020
Full Text
View/download PDF

15. Botulinum toxin type A therapy for hemifacial spasm

Author

Duarte, Gonçalo S, additional, Rodrigues, Filipe B, additional, Castelão, Mafalda, additional, Marques, Raquel E, additional, Ferreira, Joaquim, additional, Sampaio, Cristina, additional, Moore, Austen P, additional, and Costa, João, additional

Published
2020
Full Text
View/download PDF

16. Botulinum toxin type A therapy for cervical dystonia

Author

Rodrigues, Filipe B, additional, Duarte, Gonçalo S, additional, Marques, Raquel E, additional, Castelão, Mafalda, additional, Ferreira, Joaquim, additional, Sampaio, Cristina, additional, Moore, Austen P, additional, and Costa, João, additional

Published
2020
Full Text
View/download PDF

19. Characterizing White Matter in Huntington's Disease

Author

Gregory, Sarah, primary, Johnson, Eileanoir, additional, Byrne, Lauren M., additional, Rodrigues, Filipe B., additional, Henderson, Alexandra, additional, Moss, John, additional, Thomas, David, additional, Zhang, Hui, additional, De Vita, Enrico, additional, Tabrizi, Sarah J., additional, Rees, Geraint, additional, Scahill, Rachael I., additional, and Wild, Edward J., additional

Published
2019
Full Text
View/download PDF

24. Survival, mortality, causes and places of death in a european Huntington's disease prospective cohort

Author

Rodrigues, Filipe Brogueira, Abreu, Daisy, Damásio, Joana, Gonçalves, Nilza, Correia Guedes, Leonor, Coelho, Miguel, Ferreira, Joaquim J, and Repositório da Universidade de Lisboa

Subjects
Survival, Huntington's disease, Cause of death, Mortality
Abstract

© 2017 International Parkinson and Movement Disorder Society, Background: Huntington's disease (HD) is a rare and fatal inherited genetic disorder characterized by progressive motor, cognitive, and behavioral impairment. It leads to premature death, but data regarding advanced-stage disease are scarce. We sought to determine HD-associated survival, mortality, and causes and places of death. Methods: Data from the European HD Network prospective study (REGISTRY) collected from 2001 through 2013 were used, including the Unified Huntington's Disease Rating Scale and death report forms. Group comparisons were performed using the t test or the χ2 test. Survival analyses were computed through Kaplan-Meier estimates of median survival. All tests were 2-sided with a significance level of P = 0.05. Results: In total, 5164 participants were analyzed. The mean age at diagnosis was 49 years, and the mean age at death was 58 years. At the end of the study period, there were 533 deaths (10.3% of patients). Median survival was 24 years from diagnosis and 35 years from symptom onset. The most frequent causes of death were pneumonia (19.5%), other infections (6.9%), and suicide (6.6%). The most frequent places of death were the hospital (29.8%), the home (23.9%), and nursing houses (19.8%). Conclusions: Patients with HD tend to die from the same conditions as patients with other neurodegenerative diseases. However, compared with nonhereditary Parkinson's disease and Alzheimer's disease, the median time from onset to death is longer, and the places of death are distinctive.

Published
2017

25. Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?

Author

Rodrigues, Filipe Brogueira, Duarte, Gonçalo Silva, Costa, João, Ferreira, Joaquim J, Wild, Edward J., and Repositório da Universidade de Lisboa

Subjects
Tetrabenazine, Indirect comparison, Meta‐analysis, Huntington's disease, Deutetrabenazine
Abstract

© 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited., Background: Tetrabenazine is the only US Food and Drug Administration‐approved drug for Huntington's disease, and deutetrabenazine was recently tested against placebo. A switching‐trial from tetrabenazine to deutetrabenazine is underway, but no head‐to‐head, blinded, randomized controlled trial is planned. Using meta‐analytical methodology, the authors compared these molecules. Methods: RCTs comparing tetrabenazine or deutetrabenazine with placebo in Huntington's disease were searched. The authors assessed the Cochrane risk‐of‐bias tool, calculated indirect treatment comparisons, and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Results: The evidence network for this report comprised 1 tetrabenazine trial and 1 deutetrabenazine trial, both against placebo. Risk of bias was moderate in both. Participants in the tetrabenazine and deutetrabenazine trials did not differ significantly on motor scores or adverse events. Depression and somnolence scales significantly favored deutetrabenazine. Conclusion: There is low‐quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety. It is important to note that these results are likely to remain the only head‐to‐head comparison between these 2 compounds in Huntington's disease.

Published
2017

27. Botulinum toxin type A therapy for cervical dystonia

Author

Castelão, Mafalda, primary, Marques, Raquel E, additional, Duarte, Gonçalo S, additional, Rodrigues, Filipe B, additional, Ferreira, Joaquim, additional, Sampaio, Cristina, additional, Moore, Austen P, additional, and Costa, João, additional

Published
2017
Full Text
View/download PDF

33. Botulinum toxin type B for cervical dystonia

Author

Marques, Raquel E, primary, Duarte, Gonçalo S, additional, Rodrigues, Filipe B, additional, Castelão, Mafalda, additional, Ferreira, Joaquim, additional, Sampaio, Cristina, additional, Moore, A Peter, additional, and Costa, João, additional

Published
2016
Full Text
View/download PDF

37. Adaptive laboratory evolution in a novel parallel shaken pH-auxostat.

Author

Sarikaya B, Bück H, Pohen G, Rodrigues F, Günster K, Wefelmeier K, Miebach K, Blank LM, and Büchs J

Subjects
Hydrogen-Ion Concentration, Directed Molecular Evolution, Saccharomycetales growth & development, Saccharomycetales metabolism, Fermentation, Bioreactors microbiology, Culture Media chemistry
Abstract

Adaptive laboratory evolution (ALE) is a widely used microbial strain development and optimization method. ALE experiments, to select for faster-growing strains, are commonly performed as serial batch cultivations in shake flasks, serum bottles, or microtiter plates or as continuous cultivations in bioreactors on a laboratory scale. To combine the advantages of higher throughput in parallel shaken cultures with continuous fermentations for conducting ALE experiments, a new Continuous parallel shaken pH-auxostat (CPA) was developed. The CPA consists of six autonomous parallel shaken cylindrical reactors, equipped with real-time pH control of the culture medium. The noninvasive pH measurement and control are realized by biocompatible pH sensor spots and a programmable pump module, to adjust the dilution rate of fresh medium for each reactor separately. Two different strains of the methylotrophic yeast Ogataea polymorpha were used as microbial model systems for parallel chemostat and pH-auxostat cultivations. During cultivation, the medium is acidified by the microbial activity of the yeast. For pH-auxostat cultivations, the growth-dependent acidification triggers the addition of fresh feed medium into the reactors, leading to a pH increase and thereby to the control of the pH to a predetermined set value. By controlling the pH to a predetermined set value, the dilution rate of the continuous cultivation is adjusted to values close to the washout point, in the range of the maximum specific growth rate of the yeast. The pH control was optimized by conducting a step-response experiment and obtaining tuned PI controller parameters by the Chien-Hrones-Reswick (CHR) PID tuning method. Two pH-auxostat cultivations were performed with two different O. polymorpha strains at high dilution rates for up to 18 days. As a result, up to 4.8-fold faster-growing strains were selected. The increased specific maximum growth rates of the selected strains were confirmed in subsequent batch cultivations., (© 2024 The Author(s). Biotechnology and Bioengineering published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

38. Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Author

Mestre TA, Busse M, Davis AM, Quinn L, Rodrigues FB, Burgunder JM, Carlozzi NE, Walker F, Ho AK, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, and Stebbins GT

Abstract

Limitation of functional ability is a major feature of Huntington's disease (HD). The International Parkinson and Movement Disorder Society (MDS) commissioned the appraisal of the use and clinimetric properties of clinical measures of functional ability that have been applied in HD studies and trials to date, to make recommendations regarding their use based on standardized criteria. After a systematic literature search, we included a total of 29 clinical measures grouped into two categories: (1) performance-based measures (e.g., balance, walking, and reaching/grasping), and (2) rating scales. Three performance-based measures are rated as "recommended": the Tinetti Mobility Test for screening of fall risk and for severity assessment of mobility in patients with manifest HD (up to stage III); the Berg Balance Scale for severity of balance impairment; and the Six-Minute Walk Test for assessment of walking endurance (severity) in HD subjects with preserved ambulation. No rating scale targeting functional ability reached a "recommended" status either for screening or severity measurement. The main challenges identified in this review include applying widely accepted conceptual frameworks to the identified measures, the lack of validation of clinical measures to detect change over time, and absence of validated measures for upper limb function. Furthermore, measures of capacity or ability to perform activities of daily living had ceiling effects in people with early and pre-manifest HD. We recommend that the MDS prioritize the development of new scales that capture small, but meaningful changes in function over time for outcome assessment in clinical trials, particularly in earlier stages of HD.

Published
2018
Full Text
View/download PDF

39. Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort.

Author

Rodrigues FB, Abreu D, Damásio J, Goncalves N, Correia-Guedes L, Coelho M, and Ferreira JJ

Abstract

Background: Huntington's disease (HD) is a rare and fatal inherited genetic disorder characterized by progressive motor, cognitive, and behavioral impairment. It leads to premature death, but data regarding advanced-stage disease are scarce. We sought to determine HD-associated survival, mortality, and causes and places of death., Methods: Data from the European HD Network prospective study (REGISTRY) collected from 2001 through 2013 were used, including the Unified Huntington's Disease Rating Scale and death report forms. Group comparisons were performed using the t test or the χ 2 test. Survival analyses were computed through Kaplan-Meier estimates of median survival. All tests were 2-sided with a significance level of P  =   0.05., Results: In total, 5164 participants were analyzed. The mean age at diagnosis was 49 years, and the mean age at death was 58 years. At the end of the study period, there were 533 deaths (10.3% of patients). Median survival was 24 years from diagnosis and 35 years from symptom onset. The most frequent causes of death were pneumonia (19.5%), other infections (6.9%), and suicide (6.6%). The most frequent places of death were the hospital (29.8%), the home (23.9%), and nursing houses (19.8%)., Conclusions: Patients with HD tend to die from the same conditions as patients with other neurodegenerative diseases. However, compared with nonhereditary Parkinson's disease and Alzheimer's disease, the median time from onset to death is longer, and the places of death are distinctive.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results